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Vaccines, analgesia and antibiotics embody some of the most enduring therapeutic breakthroughs that have transformed medicine. Building on such fine paradigms of biomedical innovation, the evolution of technologies has increasingly sparked spectacular advances across the continuum of wellness and disease spanning medical and surgical specialties. Discovery sciencefueled by government and private sector resources -has systematically instituted the principles of modern healthcare delivery ensuring that medical practice is based on up-to-date scientific evidence. The harmony between science, technology, and resources has culminated in a golden age of discovery and translation, eradicating infections, curing cancers, and palliating endocrine and metabolic diseases. Indeed, proven therapeutic and preventive approaches have progressively moved into everyday practice.
The success of the science-medicine union has spurred public and private sector investments, further fueling the engine of discovery and enabling technology. This integration produced the new biology, enabling advances in technology platforms to offer unprecedented opportunities in disease prediction, prevention, and even cure beyond the reach of traditional healthcare solutions. Modern science offers outstanding opportunities to probe the innermost workings of the human body, and to understand how events at the subcellular and molecular levels influence the functioning and integrity of the individual as a whole. 1,2 Remarkable progress is being made in understanding the molecular, genetic, and cellular origins of disease, and opportunities now exist to uncover practical uses for this new knowledge, particularly in the realm of personalized medicine. 3, 4 Unexpectedly, however, acceleration in enabling technologies and the resultant insights into basic pathophysiological mechanisms has outstripped the capacity of current scientific and clinical structures to efficiently manage their 4 translation into new paradigms to improve the health and quality of life of individuals, communities and populations. 5 In that context, federally-funded research programs have produced hundreds, if not thousands, of new diseaserelated molecular targets that represent potential diagnostic and therapeutic targets for tailored disease management. 6 Unfortunately, their applications remain only a distant promise, reflecting a limited capacity in structures, resources and the specialized workforces required for their translations into new healthcare paradigms. Compounding these challenges is the reality that 95% of promising therapies brought into clinical development in the private sector ultimately fail because of limitations in efficacy or unacceptable toxicities. • Advancing novel molecular discoveries across the translational Valley of Death into promising technologies with a more favorable riskbenefit ratio that will appeal to the private sector for further development into novel modalities that change patient care. 8 • Consolidating the considerable resources already existing in NIH programs and cores that can facilitate the development of molecular science across the translational continuum. These will include the • Nucleating interactions between public and private sectors that maximize the utility of technology resources, distribute risk to lower barriers to commercialize diagnostics and therapeutics, and orchestrate the appropriate organizational transitions (e.g., academic-government, government-pharmaceutical company)
along the developmental continuum to optimize translational efficiencies.
• Leading the development of the next generation of clinical and translational investigators. Rebalancing the equation to equilibrate discovery and translational science will necessitate developing a cadre of investigators fluent in the lexicons of the laboratory and clinic. 10 They must understand the widely different paradigms underlying laboratory-based experimentation and clinical diagnosis and therapy, enabling integration of these structures in which critical unmet gaps in patient care drive the evolution of science. Moreover, they will require a transformation in professional culture that incents science practiced as part of multidisciplinary teams, rather than the current silos which reward individual contributions. 11, 12 The creation of the National Center for Advancing Translational Sciences evidences a broad contemporary vision of the investigational continuum from molecules, to patients and populations. It anticipates the evolution of translation from a science focused on new therapeutic modalities for disease palliation, to the assessment of risk and the science of wellness and disease prevention. 13, 14 The Center will leverage existing and emerging resources to maximize • The science of drug development traditionally has been the focus of the biopharmaceutical industry, which has been the primary source of new diagnostic and therapeutic modalities for managing patients. 15, 16 Even in the face of their considerable innovation and expertise, the success rate for new drugs is less then 5%, and success is associated advanced into clinical trials, suggest activity in the system but do not address whether this activity is optimally productive, or is even commensurate with the track record of the pharmaceutical industry, acknowledged leaders in this field. Thus, it will not be sufficient to show 9 metrics of utility or traditional markers of interim performance. Rather, the challenge will be to identify markers of performance that correlate closely with ultimate success. This is not a trivial task and the biopharmaceutical industry has been chasing this ideal, without apparent success.
• New center activities are decidedly focused on the earliest stages of the translational continuum. Indeed, the focus for this organization is on discovery, target validation, preclinical animal models, and early stage clinical trials, including T1 translation in which safety and tolerability are established, and T2 translation, in which efficacy is first explored. 1, 17 However, equally important are T3 and T4 translation. In 
